$CARM
Carisma Therapeutics Inc

2016 Q2 Form 10-Q Financial Statement

#000148500316000085 Filed on May 05, 2016

View on sec.gov

Income Statement

Concept 2016 Q2 2016 Q1 2015 Q1
Revenue $277.0K $229.0K $244.0K
YoY Change 142.98% -6.15% -57.04%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.470M $2.150M $2.600M
YoY Change 54.22% -17.31% 34.02%
% of Gross Profit
Research & Development $3.298M $4.632M $5.238M
YoY Change -47.39% -11.57% -9.98%
% of Gross Profit
Depreciation & Amortization $40.00K $50.00K $100.0K
YoY Change -55.56% -50.0% 0.0%
% of Gross Profit
Operating Expenses $6.769M $6.779M $7.841M
YoY Change -20.51% -13.54% 1.08%
Operating Profit -$6.492M -$6.550M -$7.597M
YoY Change -22.73% -13.78% 5.68%
Interest Expense $0.00 -$247.0K -$235.0K
YoY Change -100.0% 5.11% 179.76%
% of Operating Profit
Other Income/Expense, Net $1.000K -$1.024M $1.073M
YoY Change -99.93% -195.43% -3351.52%
Pretax Income -$6.490M -$7.570M -$6.520M
YoY Change -6.08% 16.1% -9.7%
Income Tax
% Of Pretax Income
Net Earnings -$6.491M -$7.574M -$6.524M
YoY Change -6.01% 16.09% -9.66%
Net Earnings / Revenue -2343.32% -3307.42% -2673.77%
Basic Earnings Per Share -$0.33 -$0.39
Diluted Earnings Per Share -$0.33 -$0.39 -$362.8K
COMMON SHARES
Basic Shares Outstanding 19.88M shares 19.68M shares 18.11M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q2 2016 Q1 2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.500M $13.40M $45.50M
YoY Change -84.11% -70.55% -15.74%
Cash & Equivalents $8.484M $13.42M $45.55M
Short-Term Investments
Other Short-Term Assets $400.0K $400.0K $600.0K
YoY Change -55.56% -33.33% 50.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $8.834M $13.81M $46.14M
YoY Change -83.77% -70.08% -15.2%
LONG-TERM ASSETS
Property, Plant & Equipment $314.0K $353.0K $422.0K
YoY Change -45.86% -16.35% -40.4%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00 $18.00K
YoY Change -100.0% -100.0% 0.0%
Total Long-Term Assets $433.0K $527.0K $440.0K
YoY Change -37.25% 19.77% -46.34%
TOTAL ASSETS
Total Short-Term Assets $8.834M $13.81M $46.14M
Total Long-Term Assets $433.0K $527.0K $440.0K
Total Assets $9.267M $14.33M $46.58M
YoY Change -83.19% -69.23% -15.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.855M $1.588M $2.043M
YoY Change -1.33% -22.27% -33.45%
Accrued Expenses $1.153M $491.0K $1.327M
YoY Change 86.57% -63.0% 190.37%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $1.000M
YoY Change -100.0% -100.0% -37.5%
Total Short-Term Liabilities $3.008M $2.282M $4.642M
YoY Change -45.03% -50.84% -26.35%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $9.000M
YoY Change -100.0% -100.0% 260.0%
Other Long-Term Liabilities $73.00K $81.00K $65.00K
YoY Change -55.49% 24.62% -67.5%
Total Long-Term Liabilities $73.00K $81.00K $65.00K
YoY Change -55.49% 24.62% -97.59%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.008M $2.282M $4.642M
Total Long-Term Liabilities $73.00K $81.00K $65.00K
Total Liabilities $3.081M $2.363M $4.707M
YoY Change -45.33% -49.8% -47.7%
SHAREHOLDERS EQUITY
Retained Earnings -$139.3M -$132.8M -$98.27M
YoY Change 32.41% 35.11% 51.62%
Common Stock $20.00K $20.00K $18.00K
YoY Change 5.26% 11.11% 12.5%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $6.173M $11.97M $30.97M
YoY Change
Total Liabilities & Shareholders Equity $9.267M $14.33M $46.58M
YoY Change -83.19% -69.23% -15.66%

Cashflow Statement

Concept 2016 Q2 2016 Q1 2015 Q1
OPERATING ACTIVITIES
Net Income -$6.491M -$7.574M -$6.524M
YoY Change -6.01% 16.09% -9.66%
Depreciation, Depletion And Amortization $40.00K $50.00K $100.0K
YoY Change -55.56% -50.0% 0.0%
Cash From Operating Activities -$5.010M -$8.550M -$8.480M
YoY Change -44.52% 0.83% 68.59%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $32.00K
YoY Change -100.0% -100.0% -36.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00 -$30.00K
YoY Change -100.0% -100.0% -40.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00 -$46.00K
YoY Change -100.0% -100.09%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 70.00K -$14.11M 0.000
YoY Change -99.59% -100.0%
NET CHANGE
Cash From Operating Activities -5.010M -$8.550M -8.480M
Cash From Investing Activities 0.000 $0.00 -30.00K
Cash From Financing Activities 70.00K -$14.11M 0.000
Net Change In Cash -4.940M -$22.66M -8.510M
YoY Change -162.22% 166.27% -118.49%
FREE CASH FLOW
Cash From Operating Activities -$5.010M -$8.550M -$8.480M
Capital Expenditures $0.00 $0.00 $32.00K
Free Cash Flow -$5.010M -$8.550M -$8.512M
YoY Change -42.87% 0.45% 67.56%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q1 dei Amendment Flag
AmendmentFlag
false
CY2016Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2016Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2016Q1 dei Document Period End Date
DocumentPeriodEndDate
2016-03-31
CY2016Q1 dei Document Type
DocumentType
10-Q
CY2016Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001485003
CY2016Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
19881725 shares
CY2016Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2016Q1 dei Entity Registrant Name
EntityRegistrantName
Eleven Biotherapeutics, Inc.
CY2016Q1 dei Trading Symbol
TradingSymbol
EBIO
CY2016Q1 ebio Change In Fair Value Of Preferred Stock Warrants
ChangeInFairValueOfPreferredStockWarrants
115000 USD
CY2016Q1 ebio Collaboration Revenue
CollaborationRevenue
203000 USD
CY2016Q1 ebio Estimated Milestone Payment To Be Received
EstimatedMilestonePaymentToBeReceived
25000000.0 USD
CY2016Q1 ebio Fair Value Assets Liabilities Transfer Between Levels
FairValueAssetsLiabilitiesTransferBetweenLevels
0 USD
CY2016Q1 ebio Research Term
ResearchTerm
P30M
CY2016Q1 ebio Working Capital Net
WorkingCapitalNet
11500000 USD
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1246000 USD
CY2016Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1588000 USD
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1794000 USD
CY2016Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
491000 USD
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
194000 USD
CY2016Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
92000 USD
CY2015Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
144126000 USD
CY2016Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
144726000 USD
CY2015Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2931033 shares
CY2016Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3530682 shares
CY2015Q4 us-gaap Assets
Assets
36825000 USD
CY2016Q1 us-gaap Assets
Assets
14333000 USD
CY2015Q4 us-gaap Assets Current
AssetsCurrent
36311000 USD
CY2016Q1 us-gaap Assets Current
AssetsCurrent
13806000 USD
CY2015Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
36079000 USD
CY2016Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
13419000 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54059000 USD
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
45549000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36079000 USD
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13419000 USD
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-8510000 USD
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-22660000 USD
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2016Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19619124 shares
CY2016Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19767545 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19619124 shares
CY2016Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19767545 shares
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
20000 USD
CY2016Q1 us-gaap Common Stock Value
CommonStockValue
20000 USD
CY2015Q4 us-gaap Construction Payable Current
ConstructionPayableCurrent
931000 USD
CY2016Q1 us-gaap Construction Payable Current
ConstructionPayableCurrent
344000 USD
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
406000 USD
CY2016Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
203000 USD
CY2015Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
96000 USD
CY2016Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
54000 USD
CY2015Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
115000 USD
CY2016Q1 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
0 USD
CY2015Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
115000 USD
CY2016Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0 USD
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.39
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
573000 USD
CY2016Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
55000 USD
CY2016Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
3700000 USD
CY2016Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y29D
CY2015Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1304000 USD
CY2016Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-115000 USD
CY2015 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.0000
CY2016Q1 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.0000
CY2015 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P1Y11M1D
CY2016Q1 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P1Y8M1D
CY2015 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.7067
CY2016Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
0 USD
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
13000 USD
CY2016Q1 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.7765
CY2015 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0106
CY2016Q1 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0073
CY2015Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2016Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-915000 USD
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2603000 USD
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2147000 USD
CY2015Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-415000 USD
CY2016Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
342000 USD
CY2015Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-598000 USD
CY2016Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1645000 USD
CY2015Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-244000 USD
CY2016Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-203000 USD
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
155000 USD
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
162000 USD
CY2015Q1 us-gaap Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
0 USD
CY2016Q1 us-gaap Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
80000 USD
CY2015Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-235000 USD
CY2016Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-247000 USD
CY2015Q1 us-gaap Interest Paid
InterestPaid
175000 USD
CY2016Q1 us-gaap Interest Paid
InterestPaid
663000 USD
CY2015Q4 us-gaap Interest Payable Current
InterestPayableCurrent
88000 USD
CY2016Q1 us-gaap Interest Payable Current
InterestPayableCurrent
0 USD
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
36825000 USD
CY2016Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14333000 USD
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7580000 USD
CY2016Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2282000 USD
CY2015Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
115000 USD
CY2016Q1 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0 USD
CY2015Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
9763000 USD
CY2016Q1 us-gaap Long Term Notes Payable
LongTermNotesPayable
0 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
0 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-14110000 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-32000 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
0 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-8478000 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-8550000 USD
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-6524000 USD
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-7574000 USD
CY2015Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1073000 USD
CY2016Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1024000 USD
CY2015Q4 us-gaap Notes Payable Current
NotesPayableCurrent
4134000 USD
CY2016Q1 us-gaap Notes Payable Current
NotesPayableCurrent
0 USD
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
7841000 USD
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
6779000 USD
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7597000 USD
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6550000 USD
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
8000 USD
CY2016Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
0 USD
CY2016Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
423000 USD
CY2016Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
81000 USD
CY2015Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1308000 USD
CY2016Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
138000 USD
CY2015Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
2000 USD
CY2016Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
26000 USD
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
32000 USD
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2016Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
232000 USD
CY2016Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
387000 USD
CY2016Q1 us-gaap Proceeds From Collaborators
ProceedsFromCollaborators
1750000 USD
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
-46000 USD
CY2016Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2016Q1 us-gaap Proceeds From Royalties Received
ProceedsFromRoyaltiesReceived
0 USD
CY2015Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
46000 USD
CY2016Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
14000 USD
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
407000 USD
CY2016Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
353000 USD
CY2015Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 USD
CY2016Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
14124000 USD
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5238000 USD
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4632000 USD
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
94000 USD
CY2016Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
174000 USD
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-125202000 USD
CY2016Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-132776000 USD
CY2015Q1 us-gaap Revenues
Revenues
244000 USD
CY2016Q1 us-gaap Revenues
Revenues
229000 USD
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
664000 USD
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
586000 USD
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
860693 shares
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.88
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
181436 shares
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
916776 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1803574 shares
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2420804 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.28
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.57
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17971000 shares
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
19639000 shares
CY2016Q1 us-gaap Write Off Of Deferred Debt Issuance Cost
WriteOffOfDeferredDebtIssuanceCost
221000 USD
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2012694 shares
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
5.14
CY2016Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.06
CY2016Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.85
CY2016Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.28
CY2016Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
118110 shares
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
18944000 USD
CY2016Q1 us-gaap Stockholders Equity
StockholdersEquity
11970000 USD

Files In Submission

Name View Source Status
0001485003-16-000085-index-headers.html Edgar Link pending
0001485003-16-000085-index.html Edgar Link pending
0001485003-16-000085.txt Edgar Link pending
0001485003-16-000085-xbrl.zip Edgar Link pending
ebio-033116x10q.htm Edgar Link pending
ebio-033116x311.htm Edgar Link pending
ebio-033116x312.htm Edgar Link pending
ebio-033116x321.htm Edgar Link pending
ebio-20160331.xml Edgar Link completed
ebio-20160331.xsd Edgar Link pending
ebio-20160331_cal.xml Edgar Link unprocessable
ebio-20160331_def.xml Edgar Link unprocessable
ebio-20160331_lab.xml Edgar Link unprocessable
ebio-20160331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending